Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, sending the British firm’s stock to its lowest in 21 months. Flutiform had not significantly reduced the yearly rate of worsening conditions in patients…